Current treatment paradigms for lupus nephritis offer significant room for improvement, according to a presenter at the ...

The following is a summary of “2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and ...

The British Society for Rheumatology has moved toward a life course approach when updating guidelines for several rheumatic ...

A new study identifies eight domains of active systemic #lupus erythematosus for defining meaningful treatment response in ...

Investigators assessed the frequency of lupus flares in patients with kidney failure undergoing dialysis or with a kidney transplant.

AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on discovery ...

Kidney fibrosis, a common endpoint of chronic kidney disease (CKD), is strongly linked to aging, with cellular senescence ...

In this randomized trial, obinutuzumab plus standard therapy was more efficacious than standard therapy alone in providing a ...

Nkarta Inc. (NASDAQ:NKTX) on Wednesday reported a first-quarter loss of 43 cents per share, beating the consensus loss of 44 ...

Despite its flawed safety and efficacy, cyclophosphamide remains the standard therapy for severe lupus nephritis. Mycophenolate mofetil shows promise as an alternative. To determine whether ...

The US regulator has started a review of Roche's supplemental biologics license application (BLA) for Gazyva/Gazyvaro (obinutuzumab) as a treatment for lupus nephritis, with a decision expected in ...